Pfizer Provides Update on Two R&D Pipeline Developments

05-Jul-2005

Pfizer Inc provided updates on two drug candidates in the company's development pipeline:

Capravirine - Pfizer is discontinuing development of capravirine, a non-nucleoside reverse transcriptase inhibitor under study for patients with HIV/AIDS who have failed on currently available antiretroviral therapies. Pfizer based the decision on results of two Phase IIb studies which failed to show a statistically-significant difference between standard triple-drug HIV therapies and the same therapy combined with capravirine. Rights to the compound will be returned to Shionogi & Co Ltd.

Daxas - Pfizer and Altana Pharma have mutually agreed to terminate a collaboration between the two companies involving the development of Daxas (roflumilast), a phosphodiesterase-4 inhibitor for chronic obstructive pulmonary disease (COPD) and asthma. Pfizer is returning all rights to the product candidate to Altana which will assume sole responsibility for the further development of Daxas.

"The search for new and innovative medicines for the treatment of HIV/AIDS, COPD and asthma remains a priority for Pfizer and we will continue to invest in other research activities in these areas to address the needs of patients and health care providers," said John LaMattina, Ph.D., president of Pfizer Global Research and Development.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances